Currently, these anti-PD-1 inhibitors have been used as monotherapy in the first-line treatment of advanced NSCLC patients with high PD-L1 expression (≥50% tumor cells) and no EGFR, ALK, or ROS1 aberrations (6). This evidence concerns the gene PDCD1 and neoplasm.